Fusion Pharmaceuticals

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers. They make money by advancing their proprietary Targeted Alpha Therapies (TATs), which combine alpha-emitting isotopes with targeting molecules to selectively deliver potent radiation to tumors while sparing normal tissue. Founded in 2014, Fusion has established significant collaborations and a robust pipeline, positioning itself as a leader in the radiopharmaceutical space.

Recent Posts by Fusion Pharmaceuticals

1-13 of 13